Inovalon (NASDAQ:INOV) updated its FY 2018 earnings guidance on Wednesday. The company provided EPS guidance of $0.27-0.34 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.35. The company issued revenue guidance of $525-545 million, compared to the consensus revenue estimate of $570.11 million.Inovalon also updated its FY 2019 guidance to $0.41-0.47 EPS.
A number of equities analysts have weighed in on the company. Wells Fargo & Co lowered their price objective on Inovalon from $14.00 to $11.00 and set a market perform rating on the stock in a research note on Thursday. Zacks Investment Research lowered Inovalon from a buy rating to a hold rating in a research note on Saturday, November 3rd. BidaskClub lowered Inovalon from a buy rating to a hold rating in a research note on Thursday, November 1st. Finally, ValuEngine raised Inovalon from a sell rating to a hold rating in a research note on Wednesday, October 17th. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the company. Inovalon presently has an average rating of Hold and a consensus target price of $10.67.
NASDAQ:INOV opened at $10.55 on Friday. Inovalon has a 52 week low of $8.90 and a 52 week high of $16.90. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 1.38. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of 45.87, a price-to-earnings-growth ratio of 2.58 and a beta of 1.02.
Inovalon Company Profile
Inovalon Holdings, Inc, a technology company, provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models in the healthcare industry. The company's platform enables the assessment and enhancement of clinical and quality outcomes and financial performance.
See Also: Correction
Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with MarketBeat.com's FREE daily email newsletter.